TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

POLYMYXIN B SULFATE
Infectious Disease Approved 1997-02-14
4
Indications
--
Phase 3 Trials
29
Years on Market

Details

Status
Prescription
First Approved
1997-02-14
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE Approval History

Loading approval history...

What TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE Treats

3 indications

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE is approved for 3 conditions since its original approval in 1997. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Ocular Bacterial Infection
  • Acute Bacterial Conjunctivitis
  • Blepharoconjunctivitis
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE FDA Label Details

Pro

Indications & Usage

Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenza and Pseudomonas aeruginosa. * *Efficacy for this organism in this organ system was studied in fewer than 10 infections.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.